Friday 16 October 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.
1.31
0.17
−11.49%
Follow AVXL
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Sep '16 | Sep '17 | Sep '18 | Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
9.19 | 27.44 | 22.93 | 22.19 | 29.25 | 152.11 | 149.16 | 151.02 | 132.19 | 102.58 |
Receivables |
0.08 | 0.01 | 1.87 | 2.64 | 4.85 | 9.14 | 3.19 | 2.71 | 2.45 | 0.81 |
Total current assets |
9.45 | 27.79 | 26.05 | 25.33 | 34.54 | 161.62 | 152.71 | 154.39 | 135.57 | 103.82 |
Long-term assets (Other) |
0.05 | 0.05 | 0.05 | — | — | — | — | — | — | — |
Total non-current assets |
0.05 | 0.05 | 0.15 | — | — | — | — | — | — | — |
Total Assets |
9.50 | 27.84 | 26.21 | 25.33 | 34.54 | 161.62 | 152.71 | 154.39 | 135.57 | 103.82 |
Accounts Payable |
3.12 | 3.58 | 2.96 | 3.52 | 3.99 | 4.74 | 3.83 | 4.32 | 9.63 | 4.25 |
Accrued Expenses |
— | — | 0.93 | 1.52 | 3.32 | 5.61 | 5.95 | 7.30 | 4.84 | 3.89 |
Current Revenue (Deferred) |
0.07 | — | — | — | — | 0.44 | 0.44 | 0.92 | 0.84 | 0.81 |
Total current liabilities |
3.19 | 3.58 | 3.88 | 5.04 | 7.31 | 10.80 | 10.21 | 12.53 | 15.30 | 8.95 |
Total liabilities |
3.19 | 3.58 | 3.88 | 5.04 | 7.31 | 10.80 | 10.21 | 12.53 | 15.30 | 8.95 |
Additional Paid In Capital |
84.29 | 115.69 | 129.38 | 153.63 | 186.85 | 348.33 | 387.98 | 434.84 | 456.25 | 477.23 |
Common Stock (Net) |
0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 |
Retained Earnings |
(78.02) | (91.48) | (107.10) | (133.40) | (159.68) | (197.59) | (245.56) | (293.07) | (336.07) | (382.45) |
Common Equity (Total) |
6.31 | 24.25 | 22.32 | 20.29 | 27.24 | 150.82 | 142.49 | 141.85 | 120.26 | 94.87 |
Shareholders Equity (Total) |
6.31 | 24.25 | 22.32 | 20.29 | 27.24 | 150.82 | 142.49 | 141.85 | 120.26 | 94.87 |
Shareholders Equity and Liabilities (Total) |
9.50 | 27.84 | 26.21 | 25.33 | 34.54 | 161.62 | 152.71 | 154.39 | 135.57 | 103.82 |
Shares (Common) |
36.17 | 43.33 | 45.93 | 52.65 | 62.05 | 75.92 | 77.94 | 82.07 | 84.80 | 86.67 |
Shareholders Equity (Tangible) |
6.31 | 24.25 | 22.32 | 20.29 | 27.24 | 150.82 | 142.49 | 141.85 | 120.26 | 94.87 |
Net Debt |
(9.19) | (27.44) | (22.93) | (22.19) | (29.25) | (152.11) | (149.16) | (151.02) | (132.19) | (102.58) |
In millions of $ except per-share values · columns are period end dates